Medpace Holdings is a holding company. Through its subsidiaries, Co. is a global provider of clinical research-based drug and medical device development services. Co. provides a suite of services supporting the entire clinical development process from Phase I to Phase IV across a range of therapeutic areas. Co.'s clinical development services include medical department, clinical trial management, data-driven feasibility, study start-up, patient recruitment and retention, clinical monitoring, risk-based monitoring, regulatory affairs, medical writing, biometrics and data sciences, pharmacovigilance, main laboratory, central laboratory, bioanalytical laboratory, clinics and quality assurance. The MEDP stock yearly return is shown above.
The yearly return on the MEDP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MEDP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|